AbbVie (NYSE:ABBV) Shares Down 1.1% – What’s Next?

08 Apr 2026, 18:00 by Teresa Graham · The Cerbat Gem

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) were down 1.1% during mid-day trading on Monday . The stock traded as low as $205.30 and last traded at $206.6240. Approximately 4,859,789 shares traded hands during mid-day trading, a decline of 33% from the average daily volume of 7,280,153 shares. The stock had previously closed at $208.84.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: AbbVie filed suit seeking clearer, narrower guidance on which patients qualify for a U.S. drug-discount program — a move investors view as defending pricing/reimbursement and limiting an expanded discount pool that could pressure revenue. AbbVie files lawsuit to address ‘outdated’ drug discount eligibility program
Positive Sentiment: New dermatology data for Skyrizi and Rinvoq highlighted at the AAD meeting reinforce long-term growth potential for AbbVie’s immunology franchise, supporting revenue upside beyond Humira. Can AbbVie’s (ABBV) New Dermatology Data Quietly Reshape Its Immunology-Heavy Investment Story?
Positive Sentiment: Analyst optimism remains: JPMorgan reiterated a bullish stance with a $260 price target, signaling confidence in upside from pipeline and operating leverage despite recent volatility. AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target Amid Competitive Concerns
Neutral Sentiment: Cantor Fitzgerald trimmed its price target from $250 to $240 but kept an overweight rating — a modestly mixed signal (lower target but still positive bias). Benzinga
Neutral Sentiment: AbbVie’s strong dividend history and large free-cash-flow generation continue to underpin investor confidence even as revenues concentrate in a few blockbuster drugs. 3 Companies Aggressively Raising Dividends While Others Play Defense
Neutral Sentiment: Corporate branding/consumer initiatives (BOTOX® Cosmetic programs, Allergan Aesthetics investments) and AMI center openings are supportive for aesthetic franchise visibility but have limited immediate earnings impact. BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through “The Confidence Collective” for Fourth Year
Negative Sentiment: AbbVie added Humira to the TrumpRx platform at a steep discount (reported ~86% in some coverage) — a direct threat to legacy Humira revenue and raises questions about future U.S. pricing strategy and margin pressure. AbbVie Puts Humira on TrumpRx at Steep Discount as Tariff Threat Solidifies
Negative Sentiment: Valuation/competition concerns persist: some analysts warn upside is limited given recent run and concentration risk in a few immunology blockbusters; that debate is keeping sentiment and volatility elevated. Why The AbbVie (ABBV) Story Is Shifting As Immunology Hopes Meet Valuation Doubts

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on ABBV shares. William Blair reissued an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. HSBC raised AbbVie from a “hold” rating to a “buy” rating and boosted their price objective for the company from $225.00 to $265.00 in a report on Wednesday, December 10th. Citigroup decreased their price objective on AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a report on Tuesday, January 27th. Finally, Wall Street Zen raised AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 28th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and an average price target of $252.65.

Check Out Our Latest Analysis on AbbVie

AbbVie Trading Up 2.6%

The company has a market cap of $374.40 billion, a price-to-earnings ratio of 89.72, a PEG ratio of 0.73 and a beta of 0.38. The business has a fifty day moving average of $220.95 and a two-hundred day moving average of $224.28.

AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.AbbVie’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. AbbVie’s dividend payout ratio is presently 293.22%.

Insider Transactions at AbbVie

In related news, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This represents a 66.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares of the company’s stock, valued at $8,771,510. The trade was a 36.98% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.25% of the company’s stock.

Hedge Funds Weigh In On AbbVie

Hedge funds have recently made changes to their positions in the company. Chelsea Counsel Co. acquired a new position in shares of AbbVie during the third quarter valued at approximately $26,000. Litman Gregory Wealth Management LLC acquired a new position in shares of AbbVie during the fourth quarter valued at approximately $28,000. Imprint Wealth LLC raised its holdings in shares of AbbVie by 56.3% during the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after acquiring an additional 45 shares during the last quarter. Westend Capital Management LLC acquired a new position in shares of AbbVie during the fourth quarter valued at approximately $29,000. Finally, IFC & Insurance Marketing Inc. acquired a new position in shares of AbbVie during the fourth quarter valued at approximately $31,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Company Profile

(Get Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.